Daxxify vs Botox: what's actually different, and who it's for.

Daxxify and Botox are both botulinum toxin type A injectables approved for glabellar (frown) lines. The marketing positions Daxxify as the longer-lasting next-generation product. The clinical story is more complicated than that. Daxxify has a real duration advantage in pivotal trials, a real onset disadvantage in real-world practice, dose math that is not 1:1, and a small but documented immunogenicity signal that, on current evidence, favors Botox in patients who plan to be on a neuromodulator for decades.

This is the comparison most patients want and most provider blogs flatten into "Daxxify lasts longer." It does — for some people, by some definitions, with tradeoffs that matter.

What each product actually is

Both are botulinum toxin type A preparations. They share the same active toxin (clostridial 150 kDa neurotoxin), the same target (presynaptic SNARE proteins at the neuromuscular junction), and the same mechanism (cleaving SNAP-25 to block acetylcholine release, producing temporary muscle paralysis).

The difference is what is packaged around the toxin.

Botox (OnabotulinumtoxinA, AbbVie/Allergan) was first approved by the FDA in 1989 for strabismus and blepharospasm, and in 2002 for the cosmetic indication that made it a household name (glabellar lines, see the FDA approval at accessdata.fda.gov). The complexing proteins it ships with — hemagglutinins and a non-hemagglutinin protein — are inherited from the Clostridium botulinum fermentation and have been part of the formulation for over three decades.

Daxxify (DaxibotulinumtoxinA-lanm, Revance Therapeutics) was approved by the FDA in September 2022 for glabellar lines, and in August 2023 for cervical dystonia. The defining feature is its excipient: RTP-004, a proprietary positively-charged peptide that stabilizes the toxin without human or animal serum components. Daxxify is the only marketed botulinum toxin A formulated without human serum albumin.

The toxin molecule itself is essentially the same. The duration claim hinges on the peptide excipient, not on a modified neurotoxin.

The duration data, honestly

In the SAKURA Phase 3 trials (cited in the Daxxify prescribing information), the median duration of effect for Daxxify on glabellar lines was approximately 6 months for "none or mild" wrinkle severity. A subset of patients maintained response at 9 months. This is roughly twice the 3-4 month median typically reported for Botox.

That is the headline number. Three caveats matter.

First, "median 6 months" is a population statistic. Individual response is variable. Real-world post-marketing experience, summarized in case series and provider surveys (see for example PMC 10880884 on toxin durability and immunogenicity), suggests many patients see 4–5 months of meaningful effect rather than 6, with a smaller cohort reporting the full 6+ months. The pivotal trial endpoint (none-or-mild wrinkle severity at maximum frown) is a clinical scoring system, not a patient satisfaction endpoint.

Second, the duration advantage is dose-dependent and dilution-dependent. Daxxify ships at 50 units per vial, reconstituted at the provider's discretion. Underdosing — using Daxxify at a Botox-equivalent unit count, which several early-adopter providers reported doing — collapses the duration advantage.

Third, "lasts longer" is not strictly an upgrade for every patient. Patients who want fine control over expression, who are pre-event-treating, or who don't yet know how they will respond to a neuromodulator may prefer a 3-month product they can adjust quickly over a 6-month product they cannot.

Dose conversion is not 1:1

Daxxify units are not equivalent to Botox units. The pivotal glabellar dose for Daxxify is 40 units total across five injection points. For Botox the standard is 20 units total across the same five points. On a unit-for-unit basis, that is roughly a 2:1 ratio, but it is not a clean conversion because:

• The 40-unit total is a fixed dose in the Daxxify protocol; it is not titrated to muscle mass the way some advanced Botox protocols are.
• Provider unit-counting practices vary, especially for off-label sites (masseter, platysmal bands, brow lift).
• Diluent volume affects spread and effective potency. Daxxify is typically reconstituted with 1.0 mL of saline for the glabellar dose.

A practical rule reported in clinical literature is that one Daxxify unit ≈ 0.5 Botox units of biologic effect for glabellar use, but this is approximate and not a substitute for following the Daxxify label.

The American Academy of Dermatology is explicit that different botulinum toxin products are not interchangeable on a unit-for-unit basis. Patients switching products should expect the new provider to re-establish dosing rather than carry over an old unit count.

Onset: Daxxify is slower

A consistent real-world signal — visible in both PMC post-marketing reviews and provider survey data — is that Daxxify takes longer to reach full effect than Botox. Many patients report partial effect at day 3 and full effect somewhere between day 7 and day 14. Botox, by comparison, is commonly described as showing effect at day 2 and reaching peak at day 7.

This matters in two clinical scenarios.

Event timing. A patient targeting a wedding or photographed event four to seven days out can usually rely on Botox to be at peak. With Daxxify, the safer recommendation is to schedule treatment at least two weeks before the event.

First-time patients. A patient who has never had a neuromodulator and is anxious about results often benefits from the faster onset of Botox: they see something is happening within 3-5 days, which builds trust before any tweaks are needed.

Cost: Daxxify is priced longer

US clinic pricing in 2025-2026 puts Daxxify roughly in the same per-treatment range as Botox, despite the higher unit count. A typical glabellar treatment runs:

The headline cost-per-treatment is higher for Daxxify, but the cost-per-month-of-effect is roughly equivalent — which is precisely how Revance positions the product. The economic argument breaks down for patients whose real-world Daxxify duration runs closer to 4-5 months than 6, and for patients whose treatment plan was already being stretched (a Botox patient who tolerates 5-month intervals between treatments may not save by switching).

Immunogenicity: the real-world question

Botulinum toxin A injections can — rarely — provoke neutralizing antibody formation, which makes the toxin progressively less effective over years of repeated injections. Across decades of Botox use, this immunogenicity signal is documented but low: clinical-significance rates in cosmetic dosing are estimated below 1% (see PMC 7269989 for a review).

Daxxify is too new for definitive long-term immunogenicity data. The Phase 3 program reported low antibody-formation rates, comparable in headline numbers to Botox. The relevant detail for patients is that Daxxify uses a novel peptide excipient (RTP-004), and although the toxin itself is the same protein, the immune environment around it differs from formulations that have been on the market for thirty-plus years.

For patients who are 30 years old and plan to use a neuromodulator into their 60s, this matters more than the duration difference. Botox has 30+ years of post-marketing immunogenicity data. Daxxify does not yet.

This is not a reason to avoid Daxxify. It is a reason to be honest that "longest available track record on antibody formation" is currently a Botox advantage, not a Daxxify one.

Off-label sites: data is still thin

The Daxxify FDA approvals cover glabellar lines and cervical dystonia. Most aesthetic neuromodulator use is off-label: masseter slimming, platysmal bands, lateral canthal lines ("crow's feet"), forehead lines, brow lift, gummy smile, DAO. Botox has off-label clinical experience and a substantial body of PubMed-indexed literature behind each of these uses going back to the early 2000s.

Daxxify clinical data for off-label aesthetic sites is accumulating — published case series, provider experience reports — but the duration claim has not been independently validated outside the glabellar studies. A provider extrapolating "6 months on the masseter" from the SAKURA glabellar endpoint is making an assumption, not citing a study.

This argues against Daxxify as a first choice for off-label sites where dosing is sensitive (masseter, where over-treatment can cause smile asymmetry) until clinic-specific dose curves are established.

Side-effect profiles are similar

Both products share the class profile: injection-site reactions (bruising, swelling, mild pain), headache, occasional eyelid or brow ptosis from local diffusion, rare allergic reactions, and the FDA boxed warning common to all botulinum toxin products about the theoretical risk of distant spread of toxin effect (clinically rare at cosmetic doses).

Daxxify's pivotal trials reported a headache rate that some commentators flagged as numerically higher than Botox's historical rate (see the FDA label for the specific incidence figures). Whether this is a meaningful difference or a population/protocol artifact has not been settled in the comparative literature.

So who is each product actually for?

The honest answer is that for the majority of glabellar-only cosmetic patients, the choice between Daxxify and Botox is not a clinical decision so much as a preference around dosing interval. For specific patient profiles the clinical answer is sharper.

Daxxify is a strong fit when:

• The patient has had Botox for years, knows their response, and wants longer intervals between treatments.
• Treatment access is a constraint (travel, schedule, geographic distance from provider).
• The patient prefers fewer touch-points per year and is willing to accept slower onset and less granular adjustability.

Botox is the better default when:

• The patient is naïve to neuromodulators and needs faster confirmation of effect.
• The patient is treating for a specific near-term event.
• The patient wants fine control over expression and the ability to adjust quickly if results are too strong.
• The treatment site is off-label (masseter, brow lift, platysmal) and dose calibration matters.
• Long-horizon immunogenicity track record is a meaningful concern.

Neither product is a clear winner. They are different tools, and the choice depends on what the patient actually values about a botulinum toxin treatment plan. A provider who recommends one over the other without asking about onset preference, event timing, and treatment history is selling a product rather than choosing a tool.

What about Dysport, Xeomin, and Jeuveau?

The Daxxify-vs-Botox conversation is the loudest, but it is not the full neuromodulator landscape. Four other botulinum toxin A products are FDA-approved for cosmetic use in the US:

• Dysport (AbobotulinumtoxinA) — faster onset (~24-48 hours), wider spread, useful for large surface areas like the forehead. Units are not interchangeable with Botox (roughly 2.5–3 Dysport units per Botox unit).
• Xeomin (IncobotulinumtoxinA) — no complexing proteins, marketed as "purified," theoretically lower immunogenicity risk.
• Jeuveau (PrabotulinumtoxinA) — clinically similar to Botox, often priced lower.

The full comparison across all five products is the subject of its own field guide. The short version: Daxxify is the longest-duration option; Dysport is the fastest-onset and widest-spread option; Xeomin is the "cleanest" formulation by immunogenicity argument; Jeuveau is the price-competitive Botox alternative; Botox is the default with the deepest track record.

Sources

• FDA Drugs@FDA, OnabotulinumtoxinA (Botox) approval history: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000
• FDA prescribing information, DaxibotulinumtoxinA-lanm (Daxxify), BLA 761127: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf
• American Academy of Dermatology, Botulinum toxin overview for patients: https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-overview
• American Society for Dermatologic Surgery, Botulinum toxin information: https://www.asds.net/skin-experts/skin-treatments/botulinum-toxin
• American Society of Plastic Surgeons, Botulinum toxin (Botox) treatment guide: https://www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin
• PMC, "Immunogenicity of botulinum toxin formulations: potential therapeutic implications," PMC 7269989: https://pmc.ncbi.nlm.nih.gov/articles/PMC7269989/
• PMC, durability and immunogenicity review of newer botulinum toxin products, PMC 10880884: https://pmc.ncbi.nlm.nih.gov/articles/PMC10880884/
• PubMed, botulinum toxin and masseter literature index: https://pubmed.ncbi.nlm.nih.gov/?term=botulinum+toxin+masseter
• FDA boxed warning on botulinum toxin products, distant spread of toxin effect: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/early-communication-about-ongoing-safety-review-botulinum-toxin